Your daily selection of the latest science news!
According to ScienceAlert
Clinical trials have begun for ViaCyte’s PEC-Direct, an implant that grows insulin-producing cells from stem cells to treat type 1 diabetes patients.
If successful, the implant could eliminate the need for these patients to inject themselves with insulin.
The World Health Organisation reports that more than 422 million people worldwide are living with diabetes, a condition that can take two forms.
In the first, the body’s immune system attacks cells in the pancreas, preventing the organ from producing enough insulin [type 1 diabetes (T1D)]. In the second, the body doesn’t know how to use the insulin that is produced [type 2 diabetes (TD2)].
T1D accounts for roughly 10 percent of diabetes cases, and unlike T2D, which can often be reversed through lifestyle changes such as weight loss or increased exercise, scientists have yet to figure out how to prevent or cure T1D.
Right now, insulin injections are the best way to manage T1D, but this method can be problematic in high-risk cases – patients with hypoglycemia (low glucose) unawareness, for example, may have trouble adjusting their insulin dosage.
This article and images were originally posted on [ScienceAlert] August 8, 2017 at 03:25AM
Credit to Author and ScienceAlert